BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conj…
Biotechnology
US, San Diego [HQ]
Document Reader
Link Index · Filing Reader · 10K/10QThis analysis tool lets you read the documents of BioAtla, Inc.
DEF 14-A Proxies
10-Ks
10-Qs
Not a single 10-Q doc.
LDA 1/2s
Click To Read:
DEF 14-A Proxies
Not a single DEF 14-A proxy doc.
10-K Filings
Not a single 10-K doc.
10-Q Filings
Not a single 10-Q doc.
LDA 1/2 Filings [Lobbying]
Not a single LDA doc.